Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402035 | 1.00 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL13458074 | 0.96 | SMN1; SMN2 (0.47) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL10803637 | 0.92 | SMN1; SMN2 (0.44) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL2493590 | 0.84 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL23731087 | 0.81 | CYP1A2 (0.64) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL256008 | 0.81 | HSD11B1 (0.48) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL28400273 | 0.80 | HSD17B1 (0.43) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL13458070 | 0.79 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2USP2TP53 | |
| SCHEMBL29664429 | 0.79 | LMNA (0.43) | RAB9ANPC1SMN1; SMN2TP53PKM | |
| SCHEMBL1740270 | 0.79 | LMNA (0.43) | RAB9ANPC1SMN1; SMN2TP53PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107177589-A | Modified active high-area carbon for fixing thimet degradation bacteria and preparation method thereof | 光合强化（北京）生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| US-8501731-B2 | Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-06 | — | — | US | claimed |
| CN-1078350-A | Synergistic composition and method for selective weed control | CIBA GEIGY AG (CH) | 1993-11-17 | — | — | CN | claimed |
| US-20250268910-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-08-28 | — | — | US | disclosed |
| EP-4559908-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | S2CBio Inc. (KR) | 2025-05-28 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119095848-A | Nicotinic acetylcholine receptor ligands | 菲利普莫里斯生产公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| CN-114478361-B | Method for preparing aza-arene compound by coupling reaction without metal catalysis | 浙江工业大学 | 2024-06-07 | — | — | CN | disclosed |
| US-4628088-A | Preparation of substituted pyridazines | ELI LILLY AND COMPANY (US) | 1986-12-09 | — | — | US | disclosed |
| US-4623376-A | PRE- AND POSTEMERGENCE | AMERICAN CYANAMID COMPANY (US) | 1986-11-18 | — | — | US | disclosed |
| US-4478999-A | Process for the preparation of phenylpyridazine compounds | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1984-10-23 | — | — | US | disclosed |
| EP-0094038-A1 | 3-Amino-6-aryl-1,2,4-triazolo(4,3-b)pyridazines, their preparation and use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-11-16 | — | — | EP | disclosed |
| US-4293554-A | Method of treating asthma | AMERICAN CYANAMID COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4230705-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4111935-A | BETA-ADRENERGIC BLOCKING AGENTS, VASODILATORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-05 | — | — | US | disclosed |
| US-4111935-A | BETA-ADRENERGIC BLOCKING AGENTS, VASODILATORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-05 | — | — | US | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | RAB9A 1384/4885NPC1 224/4885SMN1; SMN2 627/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | RAB9A 1384/4885NPC1 224/4885SMN1; SMN2 627/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | RAB9A 384/4885NPC1 399/4885SMN1; SMN2 591/4885 |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | RAB9A 1811/4885NPC1 706/4885SMN1; SMN2 2641/4885 |
| US-20250268910-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA1, CHRNG, CHRM3 | RAB9A 1403/4885NPC1 869/4885SMN1; SMN2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.